Paul Coppo

List of Publications by Year
in descending order

182 papers	8,878 citations	53794 45 h-index	45317 90 g-index
199 all docs	199 docs citations	199 times ranked	6902 citing authors

#	Article	IF	Citations
1	Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases. Journal of Nephrology, 2022, 35, 653-656.	2.0	8
2	Proteinuria Increases the PLASMIC and French Scores Performance to Predict Thrombotic Thrombocytopenic Purpura in Patients With Thrombotic Microangiopathy Syndrome. Kidney International Reports, 2022, 7, 221-231.	0.8	13
3	Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. Journal of Clinical Medicine, 2022, 11, 648.	2.4	3
4	<scp>TTP</scp>: From empiricism for an enigmatic disease to targeted molecular therapies. British Journal of Haematology, 2022, 197, 156-170.	2.5	12
5	European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis. Nephrology Dialysis Transplantation, 2022, 37, 1229-1234.	0.7	5
6	Primary Gastrointestinal Follicular Lymphomas: A Prospective Study of 31 Patients with Long-term Follow-up Registered in the French Gastrointestinal Lymphoma Study Group (GELD) of the French Federation of Digestive Oncology (FFCD). Gut and Liver, 2022, 16, 207-215.	2.9	5
7	Overexpression of IgG2 in patients resembling IgG4â€related disease with normal IgG4. Scandinavian Journal of Immunology, 2022, 95, e13126.	2.7	0
8	Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma. Haematologica, 2022, , .	3.5	1
9	Immuneâ€mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	4
10	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, 2021, 137, 733-742.	1.4	95
11	Efficacy of subcutaneous preemptive rituximab in immuneâ€mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. American Journal of Hematology, 2021, 96, E26-E29.	4.1	5
12	Should all patients with immuneâ€mediated thrombotic thrombocytopenic purpura receive caplacizumab?. Journal of Thrombosis and Haemostasis, 2021, 19, 58-67.	3.8	19
13	Immunogenic hotspots in the spacer domain of ADAMTS13 in immuneâ€mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2021, 19, 478-488.	3.8	16
14	Intensive rituximab regimen in immuneâ€mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. British Journal of Haematology, 2021, 192, e21-e25.	2.5	7
15	Firstâ€line treatment of doubleâ€hit and tripleâ€hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. American Journal of Hematology, 2021, 96, 302-311.	4.1	32
16	Combination of brentuximabâ€vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral Tâ€cell lymphoma. European Journal of Haematology, 2021, 106, 467-472.	2.2	8
17	Shiga Toxinâ€"Associated Hemolytic Uremic Syndrome in Adults, France, 2009â€"2017. Emerging Infectious Diseases, 2021, 27, 1876-1885.	4.3	8
18	Thrombotic Thrombocytopenic Purpura: When Basic Science Meets Clinical Research. Hamostaseologie, 2021, 41, 283-293.	1.9	1

#	Article	IF	Citations
19	Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management. Toxins, 2021, 13, 306.	3.4	19
20	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39
21	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
22	Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leukemia and Lymphoma, 2021, 62, 2235-2241.	1.3	4
23	N-glycanâ€“mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. Blood, 2021, 137, 2694-2698.	1.4	11
24	Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. European Journal of Internal Medicine, 2021, 93, 78-86.	2.2	9
25	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3
26	Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era. Critical Care Medicine, 2021, 49, e931-e940.	0.9	4
27	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrology, 2021, 22, 267.	1.8	24
28	News in thrombotic thrombocytopenic purpura and ADAMTS13. Hematologie, 2021, 27, 188-199.	0.0	0
29	Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP. Blood Advances, 2021, 5, 4480-4484.	5.2	6
30	Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2021, 5, 3427-3435.	5.2	16
31	Diagnosis and followâ€up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 81-93.	2.3	12
32	ADAMTS13 and von Willebrand factor assessment in steady state and acute vasoâ€occlusive crisis of sickle cell disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 197-203.	2.3	7
33	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	1.4	0
34	Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers. Nephrology Dialysis Transplantation, 2020, 35, 1538-1546.	0.7	16
35	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
36	Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. British Journal of Haematology, 2020, 188, 338-340.	2.5	7

#	Article	IF	Citations
37	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. Aids, 2020, 34, 599-608.	2.2	7
38	Antiâ€ADAMTS13 autoantibodies in immuneâ€mediated thrombotic thrombocytopenic purpura do not hamper ELISAâ€based quantification of ADAMTS13 antigen. Journal of Thrombosis and Haemostasis, 2020, 18, 985-990.	3.8	12
39	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3.8	188
40	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
41	Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab. Frontiers in Medicine, 2020, 7, 549931.	2.6	4
42	TTP in the setting of pregnancy: The story still has to be written. Journal of Thrombosis and Haemostasis, 2020, 18, 2775-2777.	3.8	10
43	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
44	Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura. HemaSphere, 2020, 4, e462.	2.7	4
45	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
46	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
47	Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2020, 105, 2619-2630.	3.5	16
48	Immune TTP pathogenesis: the rising sun on HLA. Blood, 2020, 135, 2335-2336.	1.4	0
49	HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children. Haematologica, 2020, 105, e531.	3.5	5
50	Animal models of thrombotic thrombocytopenic purpura: the tales from zebrafish. Haematologica, 2020, 105, 861-863.	3.5	5
51	Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opinion on Biological Therapy, 2019, 19, 1127-1134.	3.1	12
52	Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura. Thrombosis Research, 2019, 181, 29-35.	1.7	7
53	Risk factors associated with the human leucocyte antigen system in Lebanese patients with immune-mediated thrombotic thrombocytopenic purpura. Presse Medicale, 2019, 48, 1182-1184.	1.9	1
54	Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood, 2019, 134, 2209-2217.	1.4	38

#	Article	IF	Citations
55	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2019, 45, 1518-1539.	8.2	47
56	Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 26-37.	2.3	74
57	An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2019, 12, 383-395.	2.2	64
58	Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2019, 12, 461-471.	2.2	8
59	Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective caseâ€“control study and literature review. Rheumatology, 2019, 58, 1873-1875.	1.9	6
60	When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Transfusion and Apheresis Science, 2019, 58, 273-277.	1.0	3
61	Types of fresh plasma with focus on therapeutic plasma exchange. Transfusion and Apheresis Science, 2019, 58, 258-261.	1.0	3
62	Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic Tâ€cell lymphoma. European Journal of Haematology, 2019, 103, 35-42.	2.2	24
63	Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation. Haematologica, 2019, 104, e277-e280.	3.5	1
64	Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1537-1539.	1.6	5
65	Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura. Transfusion and Apheresis Science, 2019, 58, 102665.	1.0	2
66	Therapeutic plasma exchange in thrombotic thrombocytopenic purpura. Presse Medicale, 2019, 48, 319-327.	1.9	10
67	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, 2019, 85, 403-412.	2.4	39
68	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625
69	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica, 2019, 104, 1268-1276.	3.5	5
70	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood, 2019, 134, 4908-4908.	1.4	1
71	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. Blood, 2019, 134, 130-130.	1.4	5
72	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. Blood, 2019, 134, 2365-2365.	1.4	2

#	Article	IF	Citations
73	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366.	1.4	2
74	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. Blood, 2019, 134, 1093-1093.	1.4	0
75	Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica, 2018, 103, 1099-1109.	3.5	31
76	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leukemia and Lymphoma, 2018, 59, 1399-1405.	1.3	21
77	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2018, 103, 212-220.	3.5	62
78	FP268POST PARTUM ACUTE KIDNEY INJURY: SORTING PLACENTAL AND NON-PLACENTAL THROMBOTIC MICROANGIOPATHIES USING THE TRAJECTORY OF BIOMARKERS.. Nephrology Dialysis Transplantation, 2018, 33, i120-i121.	0.7	1
79	Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open, 2018, 02, e407-e410.	1.4	1
80	EBV infection determines the immune hallmarks of plasmablastic lymphoma. OncoImmunology, 2018, 7, e1486950.	4.6	19
81	ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshawâ€“Schulman Syndrome. Thrombosis and Haemostasis, 2018, 118, 1902-1917.	3.4	40
82	Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood, 2018, 132, 2143-2153.	1.4	102
83	A comprehensive analysis of Lymphomaâ€associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. British Journal of Haematology, 2018, 183, 68-75.	2.5	23
84	Plasma Exchanges for Refractory Evans Syndrome. Therapeutic Apheresis and Dialysis, 2018, 22, 560-562.	0.9	0
85	Pediatric thrombotic thrombocytopenic purpura. European Journal of Haematology, 2018, 101, 425-434.	2.2	45
86	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	1.4	2
87	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	1.4	3
88	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	1.4	3
89	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	1.4	3
90	Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Transfusion and Apheresis Science, 2017, 56, 52-56.	1.0	20

#	Article	IF	Citations
91	Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. American Journal of Hematology, 2017, 92, 381-387.	4.1	31
92	Thrombotic thrombocytopenic purpura. Blood, 2017, 129, 2836-2846.	1.4	457
93	Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers, 2017, 3, 17020.	30.5	242
94	Tâ€cell prolymphocytic leukemia and tuberculosis: a puzzling association. Clinical Case Reports (discontinued), 2017, 5, 1536-1541.	0.5	2
95	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids, 2017, 31, 2493-2501.	2.2	51
96	The ADAMTS13 ^{1239â€“1253} peptide is a dominant HLA-DR1-restricted CD4 ⁺ T-cell epitope. Haematologica, 2017, 102, 1833-1841.	3.5	14
97	Acute pancreatitis in immunocompromised patients: beware of varicella zoster virus primoâ€infection. Clinical Case Reports (discontinued), 2017, 5, 1261-1263.	0.5	5
98	Management of thrombotic thrombocytopenic purpura. Transfusion Clinique Et Biologique, 2017, 24, 148-153.	0.4	18
99	Thrombotic microangiopathies and antineoplastic agents. Nephrologie Et Therapeutique, 2017, 13, S109-S113.	0.5	18
100	Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS ONE, 2017, 12, e0177894.	2.5	16
101	How do I treat an hemophagocytic syndrome. Hematologie, 2016, 22, 218-233.	0.0	0
102	Twiceâ€daily therapeutical plasma exchangeâ€based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French <scp>TMA</scp> Reference Center experience. European Journal of Haematology, 2016, 97, 183-191.	2.2	23
103	Mature CD8 + Tâ€cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. Clinical Case Reports (discontinued), 2016, 4, 1088-1090.	0.5	1
104	Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematology,the, 2016, 3, e237-e245.	4.6	218
105	Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematology,the, 2016, 3, e537-e546.	4.6	53
106	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica, 2016, 101, 976-984.	3.5	70
107	Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. American Journal of Hematology, 2016, 91, 1246-1251.	4.1	46
108	Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome. Medicine (United States), 2016, 95, e5007.	1.0	5

#	Article	IF	Citations
109	Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre. Blood, 2016, 128, 136-136.	1.4	7
110	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 4617-4617.	1.4	1
111	Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. PLoS ONE, 2016, 11, e0156679.	2.5	38
112	Inflammatory and Autoimmune Manifestations Associated with Lymphoid Neoplasms: A French Multicenter Retrospective Study. Blood, 2016, 128, 5335-5335.	1.4	0
113	Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma. Blood, 2016, 128, 1832-1832.	1.4	0
114	Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study. Blood, 2016, 128, 1816-1816.	1.4	0
115	Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Blood, 2016, 128, 3730-3730.	1.4	1
116	Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Hematology American Society of Hematology Education Program, 2015, 2015, 637-643.	2.5	48
117	Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion, 2015, 55, 2445-2451.	1.6	31
118	Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Transplantation, 2015, 99, 1953-1959.	1.0	110
119	Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion, 2015, 55, 1798-1802.	1.6	20
120	Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (United States), 2015, 94, e1598.	1.0	58
121	Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? experience of the <scp>F</scp>rench thrombotic microangiopathies reference center. American Journal of Hematology, 2015, 90, E127-9.	4.1	37
122	The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. Journal of Autoimmunity, 2015, 59, 19-25.	6.5	50
123	Reply. Arthritis and Rheumatology, 2015, 67, 588-588.	5.6	0
124	Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. British Journal of Haematology, 2015, 168, 63-68.	2.5	161
125	Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. European Journal of Internal Medicine, 2015, 26, 659-665.	2.2	42
126	Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients. Blood, 2015, 126, 106-106.	1.4	1

#	Article	IF	Citations
127	Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 5506-5506.	1.4	0
128	French Observatory of Adult' Chronic Immune Thrombocytopenia (ITP) Treated By Thrombopoietin Receptor Agonists (TPO-RAs). Blood, 2015, 126, 2250-2250.	1.4	0
129	The Spectrum of Chronic CD8+ T-Cell Expansions: Clinical Features in 14 Patients. PLoS ONE, 2014, 9, e91505.	2.5	4
130	A Web-Based Delphi Study for Eliciting Helpful Criteria in the Positive Diagnosis of Hemophagocytic Syndrome in Adult Patients. PLoS ONE, 2014, 9, e94024.	2.5	65
131	Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis and Rheumatology, 2014, 66, 2613-2620.	5.6	875
132	Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 Patients. American Journal of Medicine, 2014, 127, 1118-1125.	1.5	261
133	Bilateral serous detachment of retina: an unusual mode of revelation of thrombotic thrombocytopenic purpura of favorable outcome with plasma exchange. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 181-183.	1.9	3
134	Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. International Urology and Nephrology, 2014, 46, 239-242.	1.4	28
135	Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thrombosis Research, 2014, 134, 1074-1080.	1.7	28
136	Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood, 2014, 124, 204-210.	1.4	154
137	Clinical significance of autoantibodies to the pericentromeric heterochromatin protein 1a protein. European Journal of Internal Medicine, 2013, 24, 868-871.	2.2	4
138	High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion, 2013, 54, n/a-n/a.	1.6	25
139	Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents. Leukemia and Lymphoma, 2013, 54, 1117-1119.	1.3	9
140	Thrombotic thrombocytopenic purpura in children. Current Opinion in Pediatrics, 2013, 25, 216-224.	2.0	30
141	Successful use of eculizumab in a patient with postâ€transplant thrombotic microangiopathy. British Journal of Haematology, 2013, 161, 279-280.	2.5	76
142	Response to "Predictors of survival in thrombotic thrombocytopenic purpura" Haematologica 2013;98(5):e58. Haematologica, 2013, 98, e80-e80.	3.5	0
143	Evaluation of a commercial assay for ADAMTS13 activity measurement. Thrombosis and Haemostasis, 2013, 110, 852-853.	3.4	18
144	Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center. Blood, 2013, 122, 448-448.	1.4	3

#	Article	IF	Citations
145	Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura. Blood, 2013, 122, 447-447.	1.4	0
146	Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine, 2012, 40, 104-111.	0.9	260
147	Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica, 2012, 97, 1181-1186.	3.5	118
148	Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood, 2012, 119, 5888-5897.	1.4	206
149	Causes and risk factors of death in patients with thrombotic microangiopathies. Intensive Care Medicine, 2012, 38, 1810-1817.	8.2	19
150	Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Medicale, 2012, 41, e163-e176.	1.9	57
151	Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion, 2012, 52, 2436-2444.	1.6	73
152	Acute renal failure with lambda light chain-derived crystals in a patient with IgD myeloma. Nephrology Dialysis Transplantation, 2011, 26, 3057-3059.	0.7	14
153	Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience. Blood, 2011, 118, 2229-2229.	1.4	1
154	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. Blood, 2011, 118, 2219-2219.	1.4	0
155	Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. Aids, 2010, 24, 1299-1306.	2.2	92
156	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 2010, 115, 1226-1237.	1.4	285
157	Splenic sarcoidosis: An unusual aetiology of agranulocytosis. American Journal of Hematology, 2010, 85, 891-891.	4.1	11
158	LETTERS TO THE EDITOR: Successful longâ€term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion, 2010, 50, 733-735.	1.6	18
159	Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. PLoS ONE, 2010, 5, e10208.	2.5	286
160	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial. Blood, 2010, 116, 1344-1344.	1.4	6
161	Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 36-50.	0.7	64
162	Cancer Awareness in Atypical Thrombotic Microangiopathies. Oncologist, 2009, 14, 769-779.	3.7	78

#	Article	IF	Citations
163	BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cellular Signalling, 2009, 21, 52-60.	3.6	11
164	Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatric Nephrology, 2009, 24, 19-29.	1.7	56
165	First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.. Blood, 2009, 114, 890-890.	1.4	3
166	CXCR4 Blockade as a New Targeted Therapy for Acute Myeloide Leukemia Characterised by High Cell Surface Density of CXCR4.. Blood, 2009, 114, 4570-4570.	1.4	0
167	HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.. Blood, 2009, 114, 2412-2412.	1.4	0
168	Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis and Rheumatism, 2008, 58, 1521-1527.	6.7	90
169	Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss. American Journal of Kidney Diseases, 2008, 51, 298-301.	1.9	67
170	A Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma. Blood, 2008, 112, 579-579.	1.4	9
171	Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood, 2007, 109, 2815-2822.	1.4	248
172	Involvement of STAT3 Transcription Factor in Disseminated Nasal-Type Natural Killer Cell Lymphomas.. Blood, 2007, 110, 4167-4167.	1.4	0
173	Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.. Blood, 2007, 110, 3923-3923.	1.4	0
174	BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. British Journal of Haematology, 2006, 134, 171-179.	2.5	88
175	Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases. Journal of the American Society of Nephrology: JASN, 2004, 15, 787-795.	6.1	351
176	Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement. Medicine (United States), 2004, 83, 233-244.	1.0	165
177	Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides. American Journal of Hematology, 2004, 77, 241-249.	4.1	12
178	Antineutrophil cytoplasmic antibody-associated neutropenia. European Journal of Internal Medicine, 2004, 15, 451-459.	2.2	13
179	Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?. Intensive Care Medicine, 2003, 29, 564-569.	8.2	50
180	Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene, 2003, 22, 4102-4110.	5.9	54

#	Article	IF	Citations
181	High-Dose Plasma Infusion versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/Hemolytic-Uremic Syndrome. Medicine (United States), 2003, 82, 27-38.	1.0	103
182	Allogenic bone marrow transplantation with a donor presenting with an acute hepatitis A. Journal of Hepatology, 2001, 34, 625-630.	3.7	5